Northwest Biotherapeutics (NWBO)

Northwest Biotherapeutics (NWBO) Stock Price & Analysis


NWBO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.40 - $1.27
Previous Close$0.91
Average Volume (3M)2.34M
Market Cap
Enterprise Value$1.05B
Total Cash (Recent Filing)$1.42M
Total Debt (Recent Filing)$30.76M
Price to Earnings (P/E)-11.1
May 16, 2018
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding1,086,771,876
10 Day Avg. Volume4,830,144
30 Day Avg. Volume2,335,319
Standard Deviation0.27
Financial Highlights & Ratios
Price to Book (P/B)-16.20
Price to Sales (P/S)5227.93
Price to Cash Flow (P/CF)-22.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.01K
Enterprise Value/Gross Profit7.24K
Enterprise Value/Ebitda-12.50
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Northwest Biotherapeutics’s price range in the past 12 months?
Northwest Biotherapeutics lowest stock price was $0.40 and its highest was $1.27 in the past 12 months.
    What is Northwest Biotherapeutics’s market cap?
    Currently, no data Available
    When is Northwest Biotherapeutics’s upcoming earnings report date?
    Northwest Biotherapeutics’s upcoming earnings report date is May 16, 2018 which is 1967 days ago.
      How were Northwest Biotherapeutics’s earnings last quarter?
      Currently, no data Available
      Is Northwest Biotherapeutics overvalued?
      According to Wall Street analysts Northwest Biotherapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Northwest Biotherapeutics pay dividends?
        Northwest Biotherapeutics does not currently pay dividends.
        What is Northwest Biotherapeutics’s EPS estimate?
        Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Northwest Biotherapeutics have?
        Northwest Biotherapeutics has 1,121,070,900 shares outstanding.
          What happened to Northwest Biotherapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Northwest Biotherapeutics?
          Among the largest hedge funds holding Northwest Biotherapeutics’s share is Fisher Asset Management LLC. It holds Northwest Biotherapeutics’s shares valued at N/A.


            Northwest Biotherapeutics Stock Smart Score

            The Northwest Biotherapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
            Learn more about TipRanks Smart Score

            Company Description

            Northwest Biotherapeutics

            Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. The firm engages in the development of cancer vaccines designed to treat solid tumor cancers. It also offers a platform technology for DCVax dendritic cell-based vaccines. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.


            Forecast EPS vs Actual EPS

            Similar Stocks
            Price & Change
            Cyclacel Pharmaceuticals
            Calithera Bio

            Popular Stocks

            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis